{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:45:26Z","timestamp":1782823526282,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.7759\/cureus.111804","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:00:04Z","timestamp":1782820804000},"source":"Crossref","is-referenced-by-count":0,"title":["Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)"],"prefix":"10.7759","author":[{"given":"Amal","family":"Ahad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Kolomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jada","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar I","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Sadeghzadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Yateem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punam","family":"Kharel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dristy","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alnajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muqaddas","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s I","year":"2012","unstructured":"Ord\u00e1s I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012, 380:1606-19. 10.1016\/S0140-6736(12)60150-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.07.002","article-title":"Ulcerative colitis: epidemiology, diagnosis, and management","volume":"89","author":"Feuerstein JD","year":"2014","unstructured":"Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014, 89:1553-63. 10.1016\/j.mayocp.2014.07.002","journal-title":"Mayo Clin Proc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Siew CN","year":"2017","unstructured":"Siew CN, Shi HY, Hamidi N, et al.. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017, 390:2769-78. 10.1016\/S0140-6736(17)32448-0","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s1590-8658(01)80108-0","article-title":"Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects","volume":"33","author":"Di Paolo MC","year":"2001","unstructured":"Di Paolo MC, Paoluzi OA, Pica R, et al.. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Dig Liver Dis. 2001, 33:563-9. 10.1016\/s1590-8658(01)80108-0","journal-title":"Dig Liver Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1024\/0040-5930.60.3.145","article-title":"Management of ulcerative colitis (Article in German)","volume":"60","author":"Rammert C","year":"2003","unstructured":"Rammert C, Kullak-Ublick GA. Management of ulcerative colitis (Article in German). Ther Umsch. 2003, 60:145-50. 10.1024\/0040-5930.60.3.145","journal-title":"Ther Umsch"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i1.5","article-title":"Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation","volume":"24","author":"Shen ZH","year":"2018","unstructured":"Shen ZH, Zhu CX, Quan YS, et al.. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018, 24:5-14. 10.3748\/wjg.v24.i1.5","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2974","article-title":"The gut microbiota--masters of host development and physiology","volume":"11","author":"Sommer F","year":"2013","unstructured":"Sommer F, B\u00e4ckhed F. The gut microbiota--masters of host development and physiology. Nat Rev Microbiol. 2013, 11:227-38. 10.1038\/nrmicro2974","journal-title":"Nat Rev Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2018.54.2.2760765","article-title":"Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: an update","volume":"54","author":"Holleran G","year":"2018","unstructured":"Holleran G, Scaldaferri F, Ianiro G, et al.. Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: an update. Drugs Today (Barc). 2018, 54:123-36. 10.1358\/dot.2018.54.2.2760765","journal-title":"Drugs Today (Barc)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac135","article-title":"Efficacy of fecal microbiota transplantation in the treatment of active ulcerative colitis: a systematic review and meta-analysis of double-blind randomized controlled trials","volume":"29","author":"El Hage Chehade N","year":"2023","unstructured":"El Hage Chehade N, Ghoneim S, Shah S, et al.. Efficacy of fecal microbiota transplantation in the treatment of active ulcerative colitis: a systematic review and meta-analysis of double-blind randomized controlled trials. Inflamm Bowel Dis. 2023, 29:808-17. 10.1093\/ibd\/izac135","journal-title":"Inflamm Bowel Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41182-6","article-title":"Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis","volume":"13","author":"Feng J","year":"2023","unstructured":"Feng J, Chen Y, Liu Y, et al.. Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis. Sci Rep. 2023, 13:14494. 10.1038\/s41598-023-41182-6","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i17.2666","article-title":"Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: a randomized controlled trial","volume":"29","author":"Lahtinen P","year":"2023","unstructured":"Lahtinen P, Jalanka J, Mattila E, Tillonen J, Bergman P, Satokari R, Arkkila P. Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: a randomized controlled trial. World J Gastroenterol. 2023, 29:2666-78. 10.3748\/wjg.v29.i17.2666","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fgstr.2023.1161610","article-title":"Fecal microbiota transfer to treat ulcerative colitis: medical and legal challenges","volume":"2","author":"Steube A","year":"2023","unstructured":"Steube A, Stallhofer J, Stallmach A. Fecal microbiota transfer to treat ulcerative colitis: medical and legal challenges. Front Gastroenterol (Lausanne). 2023, 2:1161610. 10.3389\/fgstr.2023.1161610","journal-title":"Front Gastroenterol (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.70389\/PJS.100082","article-title":"Transparency in the reporting of artificial intelligence-the TITAN guideline","volume":"10","author":"Agha RA","year":"2025","unstructured":"Agha RA, Mathew G, Rashid R, et al.. Transparency in the reporting of artificial intelligence-the TITAN guideline. Premier J Sci. 2025, 10:100082. 10.70389\/PJS.100082","journal-title":"Premier J Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy S","year":"2017","unstructured":"Paramsothy S, Kamm MA, Kaakoush NO, et al.. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017, 389:1218-28. 10.1016\/S0140-6736(17)30182-4","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi P","year":"2015","unstructured":"Moayyedi P, Surette MG, Kim PT, et al.. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015, 149:102-9.e6. 10.1053\/j.gastro.2015.04.001","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327811","article-title":"Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial","volume":"71","author":"Kedia S","year":"2022","unstructured":"Kedia S, Virmani S, K Vuyyuru S, et al.. Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial. Gut. 2022, 71:2401-13. 10.1136\/gutjnl-2022-327811","journal-title":"Gut"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab165","article-title":"Use of faecal transplantation with a novel diet for mild to moderate active ulcerative colitis: the CRAFT UC randomised controlled trial","volume":"16","author":"Sarbagili Shabat C","year":"2022","unstructured":"Sarbagili Shabat C, Scaldaferri F, Zittan E, et al.. Use of faecal transplantation with a novel diet for mild to moderate active ulcerative colitis: the CRAFT UC randomised controlled trial. J Crohns Colitis. 2022, 16:369-78. 10.1093\/ecco-jcc\/jjab165","journal-title":"J Crohns Colitis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00400-3","article-title":"Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Haifer C","year":"2022","unstructured":"Haifer C, Paramsothy S, Kaakoush NO, et al.. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2022, 7:141-51. 10.1016\/S2468-1253(21)00400-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01856-9","article-title":"Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study","volume":"21","author":"Crothers JW","year":"2021","unstructured":"Crothers JW, Chu ND, Nguyen LT, et al.. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. BMC Gastroenterol. 2021, 21:281. 10.1186\/s12876-021-01856-9","journal-title":"BMC Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132753","article-title":"Fecal microbial transplantation versus mesalamine enema for treatment of active left-sided ulcerative colitis-results of a randomized controlled trial","volume":"10","author":"B\u0159ezina J","year":"2021","unstructured":"B\u0159ezina J, Bajer L, Wohl P, et al.. Fecal microbial transplantation versus mesalamine enema for treatment of active left-sided ulcerative colitis-results of a randomized controlled trial. J Clin Med. 2021, 10:2753. 10.3390\/jcm10132753","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.067","article-title":"Results of the first pilot randomized controlled trial of fecal microbiota transplant in pediatric ulcerative colitis: lessons, limitations, and future prospects","volume":"161","author":"Pai N","year":"2021","unstructured":"Pai N, Popov J, Hill L, Hartung E, Grzywacz K, Moayyedi P. Results of the first pilot randomized controlled trial of fecal microbiota transplant in pediatric ulcerative colitis: lessons, limitations, and future prospects. Gastroenterology. 2021, 161:388-93.e3. 10.1053\/j.gastro.2021.04.067","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-021-01513-6","article-title":"Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study","volume":"20","author":"Fang H","year":"2021","unstructured":"Fang H, Fu L, Li X, Lu C, Su Y, Xiong K, Zhang L. Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study. Microb Cell Fact. 2021, 20:18. 10.1186\/s12934-021-01513-6","journal-title":"Microb Cell Fact"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102283","article-title":"Gut microbiome changes in patients with active left-sided ulcerative colitis after fecal microbiome transplantation and topical 5-aminosalicylic acid therapy","volume":"9","author":"Schierov\u00e1 D","year":"2020","unstructured":"Schierov\u00e1 D, B\u0159ezina J, Mr\u00e1zek J, Fliegerov\u00e1 KO, Kvasnov\u00e1 S, Bajer L, Drastich P. Gut microbiome changes in patients with active left-sided ulcerative colitis after fecal microbiome transplantation and topical 5-aminosalicylic acid therapy. Cells. 2020, 9:2283. 10.3390\/cells9102283","journal-title":"Cells"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz060","article-title":"Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study","volume":"13","author":"Sood A","year":"2019","unstructured":"Sood A, Mahajan R, Singh A, et al.. Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis. 2019, 13:1311-7. 10.1093\/ecco-jcc\/jjz060","journal-title":"J Crohns Colitis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.045","article-title":"Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis","volume":"149","author":"Rossen NG","year":"2015","unstructured":"Rossen NG, Fuentes S, van der Spek MJ, et al.. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015, 149:110-8.e4. 10.1053\/j.gastro.2015.03.045","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-025-03113-7","article-title":"Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials","volume":"29","author":"Gefen R","year":"2025","unstructured":"Gefen R, Dourado J, Emile SH, et al.. Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials. Tech Coloproctol. 2025, 29:103. 10.1007\/s10151-025-03113-7","journal-title":"Tech Coloproctol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i21.4691","article-title":"Efficacy and safety of fecal microbiota transplantation for treatment of ulcerative colitis: a post-consensus systematic review and meta-analysis","volume":"12","author":"Zhang JT","year":"2024","unstructured":"Zhang JT, Zhang N, Dong XT, Wang XR, Ma HW, Liu YD, Li MR. Efficacy and safety of fecal microbiota transplantation for treatment of ulcerative colitis: a post-consensus systematic review and meta-analysis. World J Clin Cases. 2024, 12:4691-702. 10.12998\/wjcc.v12.i21.4691","journal-title":"World J Clin Cases"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/480145-fecal-microbiota-transplantation-fmt-in-the-management-of-ulcerative-colitis-a-comprehensive-systematic-review-and-meta-analysis-of-randomized-controlled-trials-rcts","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:00:05Z","timestamp":1782820805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/480145-fecal-microbiota-transplantation-fmt-in-the-management-of-ulcerative-colitis-a-comprehensive-systematic-review-and-meta-analysis-of-randomized-controlled-trials-rcts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.111804","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}